Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/14375
Title: CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Authors: Chiorean EG
Von Hoff DD
Reni M
Arena FP
Infante JR
Bathini VG
Wood TE
Mainwaring PN
Muldoon RT
Clingan PR
Kunzmann V
Ramanathan RK
Tabernero J
Goldstein D
McGovern D
Lu B
Ko A.
Issue Date: 2016
Citation: Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.
metadata.dc.identifier.journaltitle: Ann Oncol
URI: 
metadata.dc.identifier.doi: 10.1093/annonc/mdw006
Appears in Collections:ISLHD research

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.